Trelegy Dosing When Switching from Breztri
When switching from Breztri to Trelegy for COPD, use Trelegy 100/62.5/25 mcg once daily, as this is the only FDA-approved strength for COPD treatment. 1
Dosing Rationale
The FDA label for Trelegy is explicit and unambiguous: Trelegy 100/62.5/25 mcg is the only strength indicated for the treatment of COPD 1. This recommendation applies regardless of your previous triple therapy regimen, including Breztri.
Key Dosing Details
- Administer once daily by oral inhalation at the same time each day
- Rinse mouth with water after inhalation without swallowing to reduce oropharyngeal candidiasis risk
- Do not exceed one inhalation per 24 hours
- Use a short-acting beta2-agonist (like albuterol) for breakthrough shortness of breath between doses 1
Important Considerations
No dose adjustment is needed for:
- Geriatric patients
- Patients with renal impairment
- Patients with moderate hepatic impairment 1
Clinical Evidence Supporting This Approach
The IMPACT trial (Trial 3) demonstrated that Trelegy 100/62.5/25 mcg once daily significantly reduced COPD exacerbations compared to dual therapy combinations in patients with moderate-to-severe COPD and a history of exacerbations 1. The study included 10,355 patients, with 34% previously on ICS + anticholinergic + LABA therapy (similar to Breztri's components) 1.
Real-world effectiveness data from the ELLITHE study showed clinically meaningful improvements in CAT scores (-2.6 units) and FEV1 (+93 mL) with Trelegy 100/62.5/25 mcg, with exacerbation rates dropping from 1.4 to 0.2 events per year 2.
Why Not Higher Doses?
The 200/62.5/25 mcg strength exists only for asthma, not COPD 1. Clinical trials specifically validated the 100/62.5/25 mcg dose for COPD efficacy and safety. Network meta-analyses confirm comparable efficacy across different triple therapy combinations at their approved COPD doses 3, 4.
Common pitfall to avoid: Do not attempt to "dose-match" the ICS component from Breztri to Trelegy. The FDA-approved COPD dose of Trelegy is standardized at 100 mcg fluticasone furoate, which has been proven effective in reducing exacerbations and improving lung function in the target COPD population 1.